MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome

MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome

分享

QR code

列印

我要推薦

瀏覽: 1126, 最近修訂: 2020-07-23

MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome

瀏覽: 1126, 最近修訂: 2020-07-23

間質性膀胱炎患者接受膀胱內肉毒桿菌毒素注射手術治療結果的預測因子分析

王脩仁、郭漢崇

花蓮慈濟醫院泌尿部

Predictive factors for a successful treatment outcome of intravesical Botulinum Toxin A injection for patients with Interstitial Cystitis/ Bladder Pain Syndrome

Hsiu-Jen Wang, Hann-Chrong Kuo

Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

Purpose: Intravesical onabotulinumtoxinA (BoNT-A) injection can relieve symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS). Patients with IC/BPS have different phenotypes of clinical characteristics, urodynamic, and cystoscopic findings. This retrospective study analyzed the treatment outcome and search for predictive factors for a successful treatment outcome.

Materials and Methods: Patients with IC/BPS who were treated with 100U of BoNT-A in 10ml saline injected into 20 sites were retrospectively analyzed. The treatment outcome was assessed by the global response assessment (GRA) at 6 months. We classified patients according to different clinical, urodynamic and cystoscopic characteristics (maximal bladder capacity [MBC] and glomerulation) and evaluate the treatment outcome and predictive factors.

Results: A total of 238 patients (38 males and 200 females) were included. Among them, 113 (47.5%) patients reported a successful outcome (GRA ≥ 2) and 125 (52.5%) had a unsatisfactory outcome. Patients with a GRA ≥ 2 had a significantly greater improvement of the IC symptom score, IC problem score, O’Leary Sant symptom score, and visual analog of pain score (all p=0.000) than those with a GRA ≤ 1. IC disease duration and MBC were significantly different between patients with GRA≥ 2 and GRA≤ 1. Multivariate analysis revealed that only the MBC was the predictor for a successful outcome. Patients with a MBC ≥760 ml and glomerulation of 0 or 1 (58.7%) and glomerulation of 2 or 3 (75.0%) had a successful outcome.

Conclusions: In this retrospective analysis, we found the successful result can be achieved in 47.5% of IC/BPS patients after a single BoNT-A injection, with a greater reduction of bladder pain. Patients with a MBC of ≥760ml can predict a better success rate but the glomerulation grade cannot.

Table 1. Treatment outcome based on different cystoscopic phenotype

Phenotype	GRA ≤ 1	GRA ≥ 2	Total
Glomerulation= 0,1, MBC ≥ 760 mL	19 (41.3%)	27 (58.7%)	46 (19.3%)
Glomerulation= 0,1, MBC < 760 mL	28 (60.9%)	18 (39.1%)	46 (19.3%)
Glomerulation= 2,3, MBC ≥ 760 mL	5 (25.0%)	15 (75.0%)	20 (8.4%)
Glomerulation= 2,3, MBC < 760 mL	66 (58.4%)	47 (41.6%)	113 (47.5%)
With Hunner’s lesion	7 (53.8%)	6 (46.2%)	13 (5.5%)
Total	125 (52.5%)	113 (47.5%)	238 (100%)

P= 0.024

Table 2. Changes of symptom scores and urodynamic parameters after intravesical Botox injection in IC/BPS patients with successful treatment outcome (GRA ≥ 2) and failed treatment outcome (GRA ≤ 1)

Urodynamic parameters	Time point	GRA ≤ 1 (n= 125)	GRA ≥ 2 (n= 113)	Total (n=238)
ICSI	BL FU	12.2±3.70 9.41±4.71*	12.6±3.77 4.97±3.88*#
ICPI	BL FU	11.5±3.07 9.45±4.41*	12.0±3.39 4.59±4.23*#
OSS	BL FU	23.7±6.39 18.9±8.56*	24.6±6.64 9.56±7.77*#
VAS	BL FU	4.48±32.42 3.87±3.38	5.19±2.77 2.15±2.74*#
First sensation (mL)	BL FU	112±50.5 126±67.9*	117±51.9 130±58.2*	115±51.2 128±63.2*
Full sensation (mL)	BL FU	177±74.2 190±91.1	184±73.3 205±90.0	180±7.7 197±90.6*
Urge sensation (mL)	BL FU	216±86.6 222±110	229±90.1 238±110	222±88.4 230±110
Detrusor pressure (cmH₂O)	BL FU	20.4±12.7 21.4±25.7	21.9±14.9 18.2±14.4*	21.1±13.8 19.9±20.9
Maximum flow rate (mL/s)	BL FU	12.0±6.51 10.5±5.97	12.5±4.94 12.4±6.30	12.3±5.79 11.4±6.19
Voided volume (mL)	BL FU	232±113 227±139	268±130 253±131	249±123 240±135
Post-void residual volume (mL)	BL FU	39.4±71.3 70.4±106*	26.9±53.4 48.0±82.1*	33.2±63.3 59.3±95.2*
Cystometric bladder capacity(mL)	BL FU	273±109 290±147	297±126 304±126	285±118 297±137
Bladder compliance (mL/cmH₂O)	BL FU	63.4±67.0 62.7±60.0	60.0±61.8 79.7±88.5	61.7±64.4 71.1±75.7

附件:

E-School 資料夾圖片製作.jpg (97 KB)

未登入或權限不足!

位置

資料夾名稱

摘要

發表人

TUA人資客服組

單位

台灣泌尿科醫學會

建立

2020-06-11 11:37:41

最近修訂

2020-07-23 16:33:33

MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome 分享 QR code 列印 我要推薦

MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome

MP49: Predictive factors for a successful treatment outcome of intravesical botulinum toxin a injection for patients with interstitial cystitis/ bladder pain syndrome

分享

QR code

列印

我要推薦